title: Psoriasis: the future.
abstract: The umbrella term psoriasis is now understood to incorporate several distinct phenotypes or endotypes along the disease spectrum that in turn will dictate different therapies. A stratified medicine approach to psoriasis using this clinical information coupled with pharmacogenomic and immunologic data will become more widely acceptable in the future. Comorbidities associated with psoriasis, such as diabetes, depression, and Crohn disease, and the debate about the interdependence of psoriasis and cardiovascular disease will also dictate future research and holistic and management plans for this complex disease.
authors.affiliation: Division of Dermatology, Baylor University Medical Center at Dallas, Dallas, TX, USA.
authors.forename: M Alan
authors.initials: MA
authors.lastname: Menter
authors.affiliation: Dermatology Centre, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, UK. Electronic address: Christopher.Griffiths@manchester.ac.uk.
authors.forename: Christopher E M
authors.initials: CE
authors.lastname: Griffiths
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D059451:Biosimilar Pharmaceuticals; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D010641:Phenotype; D057285:Precision Medicine; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals; D003879:Dermatologic Agents; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha
keywords: Biosimilars; Drug safety; Personalized medicine; Phenotypical variants; Psoriatic arthritis; Systemic disease